Approximately 20–50 % of pediatric patients undergoing allogeneic hematopoietic stem
cell transplantation may develop chronic Graft Versus Host Disease (GVHD) [
[1]
], which is an American Society for Apheresis (ASFA) Category II indication for Extracorporeal
Photopheresis (ECP) [
[2]
]. We were recently referred a 30 kg patient with chronic GVHD primarily affecting
the liver and integument – with prominent features being restriction in mouth opening
(due to sclerosis) and hyperpigmentation of the skin. Treatments prior to referral
included steroids, rituximab, sirolimus, and imatinib.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Chronic graft versus host disease (GVHD) in children.Pediatr Clin North Am. 2010; 57: 297-322
- Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing Committee of the American Society for Apheresis: the Eighth Special Issue.J Clin Apher. 2019; 34: 171-354
- Extracorporeal photopheresis in pediatric patients: practical and technical considerations.J Clin Apher. 2017; 32: 543-552
- An international survey of pediatric apheresis practice.J Clin Apher. 2014; 29: 120-126
- Extracorporeal photopheresis practice patterns: an international survey by the ASFA ECP Subcommittee.J Clin Apher. 2017; 32: 215-233
Article info
Publication history
Published online: June 05, 2020
Received:
March 23,
2020
Identification
Copyright
© 2020 Elsevier Ltd. All rights reserved.
